MX2010009844A - Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. - Google Patents

Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.

Info

Publication number
MX2010009844A
MX2010009844A MX2010009844A MX2010009844A MX2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A
Authority
MX
Mexico
Prior art keywords
ziprasidone
human
kits
dosage forms
cns disorder
Prior art date
Application number
MX2010009844A
Other languages
English (en)
Spanish (es)
Inventor
Dwayne Thomas Friesen
Jaymin Chandrakant Shah
William John Curatolo
Scott Max Herbig
Avinash Govind Thombre
Sheri L Shamblin
Timothy LUKAS
William Brett Caldwell
David Keith Lyon
Christopher Donovan Craig
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2010009844A publication Critical patent/MX2010009844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010009844A 2008-03-07 2009-03-04 Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. MX2010009844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
MX2010009844A true MX2010009844A (es) 2010-09-30

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009844A MX2010009844A (es) 2008-03-07 2009-03-04 Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.

Country Status (15)

Country Link
US (1) US20110002989A1 (enExample)
EP (1) EP2280711A1 (enExample)
JP (1) JP2009215293A (enExample)
KR (1) KR20100131477A (enExample)
CN (1) CN102014910A (enExample)
AR (1) AR070964A1 (enExample)
AU (1) AU2009220925A1 (enExample)
BR (1) BRPI0909818A2 (enExample)
CA (1) CA2719115A1 (enExample)
IL (1) IL207792A0 (enExample)
MX (1) MX2010009844A (enExample)
RU (1) RU2010135831A (enExample)
TW (1) TW200950783A (enExample)
WO (1) WO2009109844A1 (enExample)
ZA (1) ZA201005905B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
EP2991650A4 (en) * 2013-05-03 2017-01-25 Syndax Pharmaceuticals Inc. Methods for the treatment of cancer
TW201602108A (zh) 2013-07-30 2016-01-16 吉李德康乃狄克公司 脾酪胺酸激酶（Ｓｙｋ）抑制劑之多晶型
NZ715745A (en) 2013-07-30 2017-06-30 Gilead Connecticut Inc Formulation of syk inhibitors
EP3076951B1 (en) * 2013-12-05 2020-09-30 Celal Albayrak Process for the production of drug formulations for oral administration
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
EP3193844A1 (en) * 2014-09-19 2017-07-26 The Procter and Gamble Company Process for making a core with an active coating
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
EP3672974A1 (en) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphs of syk inhibitors
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450748A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
SG162811A1 (en) * 2005-06-20 2010-07-29 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Also Published As

Publication number Publication date
AR070964A1 (es) 2010-05-19
AU2009220925A1 (en) 2009-09-11
JP2009215293A (ja) 2009-09-24
WO2009109844A1 (en) 2009-09-11
ZA201005905B (en) 2011-11-30
BRPI0909818A2 (pt) 2015-10-06
CN102014910A (zh) 2011-04-13
IL207792A0 (en) 2010-12-30
CA2719115A1 (en) 2009-09-11
EP2280711A1 (en) 2011-02-09
TW200950783A (en) 2009-12-16
US20110002989A1 (en) 2011-01-06
KR20100131477A (ko) 2010-12-15
RU2010135831A (ru) 2012-04-20

Similar Documents

Publication Publication Date Title
MX2010009844A (es) Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.
MX2010008720A (es) Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria.
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
EA017150B9 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
PT1957061E (pt) Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
MX2011012072A (es) Lactoferrina y salud y desarrollo neuronal en el intestino infantil.
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
MX2010002410A (es) Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
GB0001449D0 (en) Compositions
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2008007227A3 (en) Method and compositions for relieving menopausal and perimenopausal symptoms
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2010001116A (es) Derivados novedosos de benzamidina, proceso para la preparacion de estos y composicion farmaceutica para la prevencion o el tratamiento de osteoporosis que comprende a los mismos.
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
EP1830814A4 (en) TASTE SUPPRESSION SYSTEM FOR NON-WEIGHTED MEDICINAL PRODUCTS
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes
Li et al. Leptin Increases Expression of 5-HT Enhancing 2B Receptors Action of in Fluoxetine Astrocytes on Thus the Depressive Behavior Induced by Sleep Deprivation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal